Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Commonwealth of Australia
Melbourne, Victoria, Australia
- Ownership
- Private
- Employees
- ~29000
- Development stage
- Other
01
Overview
CSL is a top global biotech specializing in plasma therapies and vaccines, with robust commercialized products and ongoing development in rare disease and nephrology; historic COVID-19 vaccine partnerships include AstraZeneca and University of Queensland programs.
- Therapeutic areas
- ImmunologyNephrologyInfectious DiseasesRare DiseasesHematologyNeurology
- Modalities
- Plasma-derived therapyBiologicVaccineSmall moleculeRecombinant protein
- Industry
- Pharma
02
Partnerships
University of Queensland (COVID-19 vaccine trials)AstraZeneca (COVID-19 vaccine supply/manufacturing)Novartis (influenza vaccine business acquisition)
Beyond the preview
Go deeper on Commonwealth of Australia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Commonwealth of Australia.